文献速递泌尿男性生殖肿瘤支持与姑息治疗

第二代抗雄激素与认知及功能性毒性效应的关联:随机临床试验的系统综述与Meta分析

Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Oncol · 2023-01-01

该系统综述与Meta分析纳入12项随机临床试验共13524例前列腺癌患者,评估第二代抗雄激素(阿比特龙、阿帕他胺、达罗他胺或恩扎卢胺)与认知毒性、乏力及跌倒的关联。结果显示,与对照组相比,第二代抗雄激素增加认知毒性(RR 2.10,95%CI 1.30-3.38,P=0.002)、乏力(RR 1.34,95%CI 1.16-1.54,P<0.001)和跌倒(RR 1.87,95%CI 1.27-2.75,P=0.001)风险。

要点

  • 第二代抗雄激素与认知毒性风险增加相关(RR 2.10,95%CI 1.30-3.38)。
  • 第二代抗雄激素与乏力风险增加相关(RR 1.34,95%CI 1.16-1.54)。
  • 第二代抗雄激素与跌倒风险增加相关(RR 1.87,95%CI 1.27-2.75)。

核心结论

  • 该系统综述与Meta分析提示,第二代抗雄激素携带认知与功能性毒性效应风险增加,包括在传统激素治疗基础上加用时。

研究设计与样本

  • 系统综述与Meta分析,纳入12项随机临床试验,共13524例前列腺癌患者,检索PubMed、EMBASE和Scopus(建库至2022年9月12日)。

主要发现

  • 与对照组相比,第二代抗雄激素组认知毒性风险增加(RR 2.10,95%CI 1.30-3.38,P=0.002)。
  • 与对照组相比,第二代抗雄激素组乏力风险增加(RR 1.34,95%CI 1.16-1.54,P<0.001)。
  • 在两组均接受传统激素治疗的研究中,认知毒性(RR 1.77,95%CI 1.12-2.79,P=0.01)和乏力(RR 1.32,95%CI 1.10-1.58,P=0.003)结果一致。
  • Meta回归支持年龄增加与第二代抗雄激素治疗中乏力风险增加相关(系数0.75,95%CI 0.04-0.12,P<0.001)。
  • 第二代抗雄激素与跌倒风险增加相关(RR 1.87,95%CI 1.27-2.75,P=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The use of second-generation antiandrogens (AAs) in the treatment of prostate cancer is increasing. Retrospective evidence suggests an association between second-generation AAs and adverse cognitive and functional outcomes, but further data from prospective trials are needed. OBJECTIVE: To examine whether evidence from randomized clinical trials (RCTs) in prostate cancer supports an association between second-generation AAs and cognitive or functional toxic effects. DATA SOURCES: PubMed, EMBASE, and Scopus (inception to September 12, 2022). STUDY SELECTION: Randomized clinical trials of second-generation AAs (abiraterone, apalutamide, darolutamide, or enzalutamide) among individuals with prostate cancer that reported cognitive toxic effects, asthenic toxic effects (eg, fatigue, weakness), or falls were evaluated. DATA EXTRACTION AND SYNTHESIS: Study screening, data abstraction, and bias assessment were completed independently by 2 reviewers following the Preferred Reporting Items for Systematic Reviews and Meta-analyses and Enhancing the Quality and Transparency of Health Research reporting guidelines. Tabular counts for all-grade toxic effects were determined to test the hypothesis formulated before data collection. MAIN OUTCOMES AND MEASURES: Risk ratios (RRs) and SEs were calculated for cognitive toxic effects, asthenic toxic effects, and falls. Because fatigue was the asthenic toxic effect extracted from all studies, data on fatigue are specified in the results. Meta-analysis and meta-regression were used to generate summary statistics. RESULTS: The systematic review included 12 studies comprising 13 524 participants. Included studies had a low risk of bias. An increased risk of cognitive toxic effects (RR, 2.10; 95% CI, 1.30-3.38; P = .002) and fatigue (RR, 1.34; 95% CI, 1.16-1.54; P < .001) was noted among individuals treated with second-generation AAs vs those in the control arms. The findings were consistent in studies that included traditional hormone therapy in both treatment arms for cognitive toxic effects (RR, 1.77; 95% CI, 1.12-2.79; P = .01) and fatigue (RR, 1.32; 95% CI, 1.10-1.58; P = .003). Meta-regression supported that, across studies, increased age was associated with a greater risk of fatigue with second-generation AAs (coefficient, 0.75; 95% CI, 0.04-0.12; P < .001). In addition, the use of second-generation AAs was associated with an increased risk of falls (RR, 1.87; 95% CI, 1.27-2.75; P = .001). CONCLUSIONS AND RELEVANCE: The findings of this systematic review and meta-analysis suggest that second-generation AAs carry an increased risk of cognitive and functional toxic effects, including when added to traditional forms of hormone therapy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Nowakowska MK, Ortega RM, Wehner MR, et al. Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2023. PMID: 37227736. doi:10.1001/jamaoncol.2023.0998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。